Hope on the Horizon—New Alzheimer’s Drug Shows Promise

Intermediate | September 2, 2025

✨ Read the article aloud on your own or repeat each paragraph after your tutor.

A Big Step Forward: New Alzheimer’s Drug Shows Promise

In late August 2025, researchers announced that Leqembi (lecanemab) has been shown to slow memory loss in early-stage Alzheimer’s patients by about 30% over an 18-month period. This result marks a meaningful breakthrough in the fight against cognitive decline. The new Alzheimer’s drug shows promise of giving patients and families more time together. (cbsnews.com)

What Is Leqembi?

Leqembi is a monoclonal antibody that targets the amyloid-beta protein, helping to clear clusters of toxic plaques in the brain—one of Alzheimer’s key causes. In clinical trials involving nearly 1,800 participants, this new Alzheimer’s drug shows promise by slowing cognitive decline significantly compared to placebo. (en.wikipedia.org)

How Big Is the Impact?

While no cure exists yet, patients taking Leqembi experienced roughly 27% less decline on clinical measures than those on placebo after 18 months. That’s like gaining back a few precious moments of clarity and memory. (en.wikipedia.org)

Why This Matters for You

It’s real-world Business English: terms like monoclonal antibody, clinical trial, and cognitive decline are part of today’s medical/business dialogue.
The story connects science, health, and hope—perfect for lively classroom conversation.
It shows how medical innovation can make complex topics more approachable in English learning.

Vocabulary (10 words)

Monoclonal antibody (noun) – a lab-made protein that can bind to a specific target like amyloid.
- Example: Leqembi is a monoclonal antibody targeting Alzheimer’s plaques.
Amyloid-beta (noun) – a protein that forms harmful clumps in the brain.
- Example: Leqembi helps remove amyloid-beta plaques.
Placebo (noun) – a harmless treatment with no active drug, used for comparison.
- Example: Patients in the placebo group showed more decline.
Cognitive (adjective) – related to thinking or memory.
- Example: Leqembi slowed cognitive decline in patients.
Decline (noun) – gradual reduction in function.
- Example: Alzheimer’s causes a decline in memory.
Breakthrough (noun) – an important scientific leap forward.
- Example: The results are a major breakthrough in Alzheimer’s treatment.
Target (verb) – to focus treatment on something.
- Example: Leqembi targets harm-causing amyloid plaques.
Symptom (noun) – a sign of illness.
- Example: Memory loss is a common symptom of Alzheimer’s.
Modest (adjective) – moderate in size or effect.
- Example: The drug delivered a modest but meaningful improvement.
Trial (noun) – a study testing a drug.
- Example: The phase III trial measured Leqembi’s effect on memory loss.

Discussion Questions (About the Article)

What does Leqembi target in the brain to slow Alzheimer’s?
By how much did the new Alzheimer’s drug show promise in slowing cognitive decline?
What does it mean that Leqembi showed a “modest benefit”?
Why is slowing decline by just 27–30% still important?
What are possible next steps for research on this drug?

Discussion Questions (About the Topic)

Why is it hard to find a cure for Alzheimer’s?
How can new medical vocabulary be taught effectively to learners?
What roles do clinical trials play in medical breakthroughs?
Would you consider taking a new drug with modest benefits? Why or why not?
How does medical news like this affect public perception of hope and progress?

Related Phrase or Idiom

Phrase: “Hold out hope” – to stay optimistic that something good will happen.

Example: Families facing memory loss can still hold out hope with treatments like Leqembi showing real promise.

📢 Want more tips like this? 👉 Sign up for the All About English Mastery Newsletter! Click here to join us!

Want to finally Master English but don’t have the time? Mastering English for Busy Professionals is the course for you! Check it out now!

Follow our YouTube Channel @All_About_English for more great insights and tips.

This article was inspired by CBS News and Wikipedia entries on Leqembi (lecanemab), as well as a University of Washington Newsroom video.